O.10 Cardiotoxicity of immune checkpoint inhibitors (ICI): a systematic review and meta-analysis of randomized clinical trials

BJMO - 2021, issue 3, march 2021

Elisa Agostinetto , Daniel Eiger , Matteo Lambertini , Marcello Ceppi , Marco Bruzzone , Noam Ponde , Chris Plummer , Ahmad Hussein Awada , Martine Piccart-Gebhart , Evandro de Azambuja

Introduction: ICI can cause potentially life-threatening adverse events (AE) and their risk of cardiotoxicity has been poorly investigated. It is also unknown whether ICI combinations increases cardiotoxicity compared to single ICI. We aimed to assess the cardiotoxicity rate of ICI compared to other cancer treatments (primary objective) and of dual-agent ICI (immunotherapy combinations) compared to single-agent ICI (secondary objective).

Read more

Lessons learned after two decades of international academic clinical research in breast cancer (BC)

BJMO - 2019, issue 2, february 2019

Martine Piccart-Gebhart

The Breast International Group (BIG), founded in 1999, is today the largest academic network in the world dedicated to conducting research designed to accelerate and refine the use of anticancer treatments and diagnostic tools for the benefit of women and men with breast cancer (BC).

BIG’s collaborative research model provides academic leadership in industry-sponsored randomized clinical trials. Some of these trials have successfully led to the rapid registration of new anticancer drugs with a significant impact on breast cancer mortality, such as the HERA trial.

BIG also supports clinical trials sponsored by its academic member groups and facilitates collaboration between international researchers and the US cooperative groups: the SOFT and TEXT trials evaluating adjuvant endocrine therapies for 5,738 premenopausal women are an example of such a collaboration.

Despite its success, BIG and its affiliated cooperative groups must battle constantly to remain vigorously involved in clinical trial design and conduct and in translational research. Without academic leadership in the research process, critical issues important for patient care will remain unaddressed. Moreover, healthcare costs will continue to rise substantially as a consequence of the worrisome “add on” approach in registration trials.

This talk will try to formulate important messages for the next generation of oncology leaders.

Read more